CS
AKRO

Candriam SCA’s Akero Therapeutics AKRO Stock Holding History

Candriam SCA’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-240,000
Closed -$6.06M – 689
2024
Q1 		$6.06M Buy
240,000
+56,000
+30% +$1.35M 0.04% 309
2023
Q4 		$4.3M Buy
184,000
+84,000
+84% +$1.66M 0.03% 350
2023
Q3 		$5.06M Sell
100,000
-15,000
-13% -$698K 0.04% 311
2023
Q2 		$5.37M Buy
115,000
+10,000
+10% +$458K 0.04% 327
2023
Q1 		$3.7M Sell
105,000
-105,000
-50% -$4.68M 0.03% 433
2022
Q4 		$11.5M Buy
+210,000
New +$9M 0.08% 245
2022
Q1 		– Sell
-88,876
Closed -$1.88M – 808
2021
Q4 		$1.88M Sell
88,876
-37,791
-30% -$838K 0.01% 559
2021
Q3 		$2.83M Hold
126,667
– – 0.02% 508
2021
Q2 		$3.14M Buy
126,667
+30,269
+31% +$850K 0.02% 499
2021
Q1 		$2.39M Hold
96,398
– – 0.02% 494
2020
Q4 		$2.49M Sell
96,398
-3,102
-3% -$86.3K 0.02% 506
2020
Q3 		$3.06M Sell
99,500
-58,500
-37% -$2.04M 0.03% 434
2020
Q2 		$3.94M Buy
158,000
+138,000
+690% +$3.15M 0.04% 380
2020
Q1 		$434K Hold
20,000
– – ﹤0.01% 722
2019
Q4 		$444K Hold
20,000
– – ﹤0.01% 740
2019
Q3 		$455K Hold
20,000
– – 0.01% 691
2019
Q2 		$381K Buy
+20,000
New +$379K ﹤0.01% 768

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Candriam SCA's AKRO Position: Q2 2024 in Review

Candriam SCA sold out of Akero Therapeutics (AKRO) in Q2 2024, closing a stake of 240,000 shares — an estimated $6.06M sold.

Candriam SCA first reported a position in AKRO in Q2 2019 and held it in 17 quarters. The position peaked at $11.5M in Q4 2022. 153 funds tracked by Wall St. Rank hold AKRO as of Q2 2024.

  • Candriam SCA reported no remaining Akero Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Candriam SCA sold 240,000 Akero Therapeutics shares in Q2 2024, an estimated $6.06M.
  • Candriam SCA first reported a position in Akero Therapeutics in Q2 2019 and held it in 17 quarters.
  • Candriam SCA's Akero Therapeutics position peaked at $11.5M in Q4 2022.
  • 153 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2024.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.